Protara Therapeutics, Inc.TARANASDAQ
LOADING
|||
Switch Symbol:
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | -11.76% |
| Q2 2025 | 17.73% |
| Q1 2025 | -3.70% |
| Q4 2024 | 17.71% |
| Q3 2024 | 26.35% |
| Q2 2024 | -16.67% |
| Q1 2024 | 20.12% |
| Q4 2023 | 2.62% |
| Q3 2023 | -14.20% |
| Q2 2023 | 40.91% |
| Q1 2023 | 3.09% |
| Q4 2022 | 43.94% |
| Q3 2022 | 12.39% |
| Q2 2022 | -41.47% |
| Q1 2022 | 29.52% |
| Q4 2021 | -0.61% |
| Q3 2021 | -30.47% |
| Q2 2021 | -16.38% |
| Q1 2021 | 92.81% |
| Q4 2020 | 30.59% |
| Q3 2020 | 13.21% |
| Q2 2020 | -19.42% |
| Q1 2020 | 196.23% |
| Q4 2019 | -389.91% |
| Q3 2019 | 11.34% |
| Q2 2019 | -8.45% |
| Q1 2019 | -2.81% |
| Q4 2018 | -52.89% |
| Q3 2018 | -14.71% |
| Q2 2018 | -32.19% |
| Q1 2018 | 26.79% |
| Q4 2017 | -68.96% |
| Q3 2017 | 165.81% |
| Q2 2017 | -8.47% |
| Q1 2017 | -4.28% |
| Q4 2016 | -8.26% |
| Q3 2016 | -7.63% |
| Q2 2016 | 20.46% |
| Q1 2016 | 21.51% |
| Q4 2015 | 16.23% |